A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

Abstract

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.

• Authors: M Farlow, R Anand, J Messina Jr, R Hartman, J Veach
• Journal: European neurology (Eur Neurol) Vol. 44 Issue 4 Pg. 236-41 ( 2000) ISSN: 0014-3022 [Print] Switzerland
• PMID: 11096224 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
• Copyright: Copyright 2000 S. Karger AG, Basel

Chemical References

• Carbamates
• Cholinesterase Inhibitors
• Phenylcarbamates
• Rivastigmine

Topics

• Age Factors
• Aged
• Alzheimer Disease (diagnosis, drug therapy, physiopathology)
• Carbamates (administration & dosage, adverse effects)
• Cholinesterase Inhibitors (administration & dosage, adverse effects)
• Cognition (drug effects, physiology)
• Disease Progression
• Dose-Response Relationship, Drug
• Double-Blind Method
• Humans
• Phenylcarbamates
• Rivastigmine
• Time Factors
• Treatment Outcome